Clovis Oncology Inc.'s PARP inhibitor Rubraca (rucaparib) has shown a benefit on progression-free survival in the ARIEL3 study in a wider range of ovarian cancer patients than its current label covers. The company will use the data for an sNDA application within the next four months for a second-line and later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who have responded to their most recent platinum therapy.
Shares in Clovis shot up by as much as 45% on Nasdaq on the announcement on the morning of June...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)